Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations

Colletti, Giacomo; Dalmonte, Pietro; Moneghini, Laura; Ferrari, Daris; Allevi, Fabiana

doi:10.1016/j.mehy.2015.05.016

Cited by 21 publications

(9 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, some of these complicated VAs are refractory to the abovementioned treatment modalities. In these cases, rapamycin (mTOR) inhibitors are found to be more promising (9)(10)(11)(12)(13)(14)(15)(16).…”

mentioning

confidence: 99%

Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review

Sandbank¹,

Molho‐Pessach²,

Farkas³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta Acta Derm Venereol 2019; 99: 990-996 990 SIGNIFICANCEIn recent years, sirolimus, an mTOR inhibitor, has become a new therapeutic option for patients with vascular anomalies that do not respond to other treatments. We report here a retrospective series of 19 young adults, children and neonates with complex vascular anomalies treated with sirolimus. Overall, clinical improvement was demonstrated in 15 patients (79%). In addition, an up-to-date literature review was performed and 150 cases of vascular anomalies treated with sirolimus were analysed. The results suggest that sirolimus is an effective and safe treatment. Further study is needed into the early use of sirolimus in cases of low-flow lesions, and overgrowth syndromes with low-flow components.Vascular anomalies (VAs) may be associated with significant morbidity and mortality. The aim of this study was to evaluate the efficacy and safety of sirolimus (rapamycin) in the treatment of children and young adults with complicated VAs. A retrospective chart was created that included 19 patients treated with sirolimus for complicated VAs. Concurrently, a search of the PubMed database for VA cases treated with sirolimus was conducted. Descriptive analysis was performed and the efficiency rate of sirolimus was calculated. This retrospective study included 19 patients, 17 of whom were treated with oral sirolimus and 2 with topical sirolimus. Clinical improvement occurred in 15 patients (79%). One patient experienced near-complete resolution. Only 2 patients showed poor response and discontinued treatment. The literature review analysed 150 cases of VA treated with sirolimus. Sirolimus was efficient in 85% of cases, including 5 cases of complete resolution. Sirolimus appears to be an effective and safe treatment for children and young adults with complicated VAs.

show abstract

mentioning

confidence: 99%

Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review

Sandbank¹,

Molho‐Pessach²,

Farkas³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…[ 17 18 ] Other medications that have been tried include tetracyclines as vasculostatic agents in brain AVMs, interferon, and VEGF (vascular endothelial growth factor) inhibitors, particularly in visceral and cranial AVMs. [ 19 ]…”

Section: Discussionmentioning

confidence: 99%

Peripheral arteriovenous malformations—A case series

Mathew

George

Meeniga

et al. 2020

Indian Dermatol Online J

View full text Add to dashboard Cite

“…The mentioned authors studied the mitogenactivated protein kinase signaling pathway in their case, considering that it contributes to the progression of AVMs in a related fashion to capillary malformations (Tan, Chernova, & Gao, 2014) and propranolol could interfere in this pathway (Lu et al, 2018). The other two possible mechanisms in the antiangiogenic effect could be inhibition of vascular endothelial growth factor and other proangiogenic proteins (e.g., ENG and ALK1; Coletti, Dalmonte, Monenghini, Ferrari, & Allevi, 2015) as well as through blockage of β-adrenergic receptors expressed on the MAV vessels. Of note, AVMs in other locations have also been benefited of beta-blockers as palliative treatment (Kowacs & Werneck, 1996).…”

Section: Discussionmentioning

confidence: 99%

Oral propranolol as palliative treatment for a recurrent arteriovenous malformation

Rodríguez‐Jiménez

Uceda

Ramírez-Bellver

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations

Cited by 21 publications

References 51 publications

Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review

Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review

Peripheral arteriovenous malformations—A case series

Oral propranolol as palliative treatment for a recurrent arteriovenous malformation

Contact Info

Product

Resources

About